中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.023 seconds)

    DETERMINING A NORMALIZED EXPRESSION OF ONE OR MORE S100A AND S100A9 POLYPEPTIDE EXPRESSION PRODUCTS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION
    2.
    发明专利
    DETERMINING A NORMALIZED EXPRESSION OF ONE OR MORE S100A AND S100A9 POLYPEPTIDE EXPRESSION PRODUCTS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION 未知

    公开(公告)号：CA2938893C

    公开(公告)日：2022-12-13

    申请号：CA2938893

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: C12Q1/6809 ,  C12Q1/68 ,  G01N33/48 ,  G01N33/53 ,  G16B25/10

    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

    Métodos y composiciones para evaluar injertos pulmonares
    4.
    发明专利
    Métodos y composiciones para evaluar injertos pulmonares 未知

    公开(公告)号：ES2831400T3

    公开(公告)日：2021-06-08

    申请号：ES14754767

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: G01N33/68

    Abstract: Método para clasificar un injerto pulmonar sometido a perfusión pulmonar ex vivo (PPEV) normotérmica, durante la perfusión y/o después de la perfusión, comprendiendo el método: a) recoger una muestra de ensayo del injerto pulmonar, en donde el injerto pulmonar es de un donante en muerte cardíaca (DMC); b) medir un nivel de polipéptido de un producto génico predictor de endotelina seleccionado de endotelina 1 (ET-1) y ET-1 grande en la muestra de ensayo; e c) identificar el injerto pulmonar como un buen candidato para trasplante o como un mal candidato para trasplante, en donde un nivel de polipéptido aumentado del producto génico predictor de endotelina en comparación con un control de pronóstico es indicativo de que el injerto es un mal candidato para trasplante.

    METHODS AND COMPOSITIONS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION
    5.
    发明专利
    METHODS AND COMPOSITIONS FOR ASSESSING CHRONIC ALLOGRAFT DYSFUNCTION 未知

    公开(公告)号：CA2938893A1

    公开(公告)日：2014-08-28

    申请号：CA2938893

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: C12Q1/68 ,  C12Q1/6809 ,  G01N33/48 ,  G01N33/53 ,  G06F19/20 ,  G16B25/10

    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS
    6.
    发明专利
    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS 未知

    公开(公告)号：CA2935866A1

    公开(公告)日：2014-08-28

    申请号：CA2935866

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: G01N33/48 ,  G01N33/483 ,  G01N33/53 ,  G01N33/543

    Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.

    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS
    7.
    发明公开
    METHODS AND COMPOSITIONS FOR ASSESSING LUNG GRAFTS 审中-公开
    方法和组合物评估肺移植

    公开(公告)号：EP2959292A4

    公开(公告)日：2016-12-14

    申请号：EP14754767

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: G01N33/68 ,  C40B30/02

    CPC classification number: G01N33/6884 ,  C40B30/02 ,  G01N33/68 ,  G01N2333/5754 ,  G01N2800/245

    Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.

    METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION
    8.
    发明公开
    METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION 审中-公开
    法测量确定用于慢性肺移植功能障碍同种异体的风险的IL-6表达的抑制

    公开(公告)号：EP2959017A4

    公开(公告)日：2017-01-11

    申请号：EP14754331

    申请日：2014-02-20

    Applicant: UNIV HEALTH NETWORK

    Inventor： KESHAVJEE SHAF ,  LIU MINGYAO ,  CYPEL MARCELO

    IPC: C12Q1/68 ,  G01N33/48 ,  G01N33/53 ,  G06F19/20

    CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/6869 ,  G01N2333/4727 ,  G01N2333/5412 ,  G01N2333/5428 ,  G01N2800/245 ,  G01N2800/50

    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

Patent Agency Ranking